2024 ASCO GI | CLDN18.2 Chimeric Antigen Receptor T Cell Therapy for Patients with Advanced Gastric and Pancreatic Adenocarcinoma: Results of ELIMYN18.2 Phase 1b Clinical Trial

2023 ASH | Three-Year Follow-up on Efficacy and Safety Results from Phase I Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

2023 SITC | Case Report: Metastatic Gastrointestinal Cancer Patient Responded to Repeated Administration of Anti-Claudin 18.2 CAR-T cells

2023 ASCO | Circulating Tumor DNA and Association with CAR T-cell Therapy Response in Gastric and Pancreatic Cancer Patients

2023 ASCO | Phase I Trial of Chimeric Anti-GPC3 scFv-CD3ε Engineered T Cells (CT0180) in Patients with Advanced Hepatocellular Carcinoma

2023 AACR | CLDN18.2 expression is associated with clinicopathological features and prognosis of Chinese patients with digestive system cancers: a retrospective analysis